WO2015127147A2 - Dispositif d'inhalation et procédé permettant d'inhaler des poudres - Google Patents

Dispositif d'inhalation et procédé permettant d'inhaler des poudres Download PDF

Info

Publication number
WO2015127147A2
WO2015127147A2 PCT/US2015/016720 US2015016720W WO2015127147A2 WO 2015127147 A2 WO2015127147 A2 WO 2015127147A2 US 2015016720 W US2015016720 W US 2015016720W WO 2015127147 A2 WO2015127147 A2 WO 2015127147A2
Authority
WO
WIPO (PCT)
Prior art keywords
inhalation
lpm
diameter
powder
microns
Prior art date
Application number
PCT/US2015/016720
Other languages
English (en)
Other versions
WO2015127147A3 (fr
Inventor
David Brown
Original Assignee
David Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Brown filed Critical David Brown
Priority to EP15752858.9A priority Critical patent/EP3107606A4/fr
Priority to CN201580006645.9A priority patent/CN106255524B/zh
Priority to US15/119,128 priority patent/US10857315B2/en
Priority to JP2016552345A priority patent/JP2017506106A/ja
Publication of WO2015127147A2 publication Critical patent/WO2015127147A2/fr
Publication of WO2015127147A3 publication Critical patent/WO2015127147A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A61M15/0098—Activated by exhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/06—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump
    • B05B11/062—Gas or vapour producing the flow, e.g. from a compressible bulb or air pump designed for spraying particulate material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2209/00—Ancillary equipment
    • A61M2209/06—Packaging for specific medical equipment

Definitions

  • the present invention relates to method of dispersing powders and, in particular or in a preferred embodiment, to a method of inhaling powders and to a device for dispersing and, in particular or in a preferred embodiment, for inhaling powders.
  • Dispersion of powders is important for a number of fields and, in particular, in the field of medicine. Inhalation has become the primary route of administration in the treatment of asthma and COPD and has been demonstrated and even commercialized for the treatment of systemic diseases such as diabetes. This is because, in addition to providing direct access to the lungs, medication delivered through the respiratory tract provides rapid and predictable onset of action and requires lower dosages compared to, for instance, the oral route where the active ingredient must first pass through at least part of the digestive tract before absorption into the bloodstream.
  • Pressurized metered dose inhalers are a commonly used inhalation devices. Such devices comprise a canister containing a suspension of fine drug particles in a propellant. Upon actuation, the aerosol contents are expelled through a metering valve and a metered dose is propelled into the lungs of the patient.
  • pMDIs Pressurized metered dose inhalers
  • propellants namely chlorofluorocarbons (CFCs)
  • CFCs chlorofluorocarbons
  • pMDIs also require coordinated actuation and inhalation by the patient for proper lung deliver.
  • DPIs dry powder inhalers
  • the powdered medicament can be arranged as unit dose containers, e.g. blister packs, cartridges or peelable strips, which are opened in an opening station of the device.
  • the unit dose is measured from a powder reservoir by means of a metering member, e.g. a dosing cup.
  • fine "active" ingredient e.g. drug particles of respirable size are typically mixed with coarser carrier particles to form an ordered mixture, wherein the fine active particles are attached to the larger carrier particles.
  • This technique complicates the powder aerosol ization process and, in particular, necessitates the breakup of the active/carrier agglomerates before they enter the patient's mouth and throat, where individual large particles and agglomerated large and small active particles tend to deposit.
  • Effective aerosol ization and deagglomeration of the powder requires that forces exerted on particles (be they on exposed surfaces of the device, between active and carrier particles or between active and active particles) must be overcome under all expected inhalation profiles.
  • the aim of an inhaler devices is to produce a high Fine Particle Dose (FPD) of particles in the respirable size range.
  • FPD Fine Particle Dose
  • the ability of a device to aerosolize and deagglomerate the active particles into a respirable particle size range depends on the patient's inspiration technique for most DPIs currently available.
  • An ideal dry powder inhaler would provide uniform powder aerosol ization and deagglomeration over a wide range of inhalation profiles, so as to generate consistent doses of respirable particles in the final dispersion.
  • the current invention offers a means to overcome the limitations of the existing inhalation methods and devices by offering a simple, low cost, high efficiency, safe and user friendly inhalation technology which is a benefit to industry and commerce.
  • the purpose of the present invention is to provide a means of overcoming the difficulties of existing powder aerosol ization and dispersion techniques to provide a small and convenient delivery device for safe and effective dispersion and delivery of fine powders of, for instance, API's.
  • the method can be used to create an aerosol cloud from a powder, direct an aerosol cloud or, in particular or in a preferred embodiment, to deliver a powder to the deep lung and to provide a device capable of carrying out said means.
  • the technology may also be applied for powder delivery to other destinations such as the nasal membrane, to expel a cloud of powder into a vessel or open space or to direct a cloud or powder, for instance, a powder containing an irritant, to, for instance, the face and/or eyes of an attacker.
  • An aspect of embodiments of the present invention is focused on a method for delivering an aerosol of powder, preferably inhalation powder, having the following steps:
  • Another aspect of embodiments of the present invention is focused on a device for dispersing and/or delivering a powder or an aerosol of powder, preferably an inhalation powder, having all or part of said powder positioned in a passage wherein the passage has one or more exits, one or more inlets and one or more obstructions to block the movement or to contain the powder within the inhalation device before use, the one or more obstructions being breachable up the application of a pressure differential between the one or more exits and inlets of the passage.
  • a device or inhalation device is understood to be any device suited to carrying out the described method for dispersing and/or delivering powder or an aerosol of powder.
  • a device is said to be activated or in use when a breaching pressure differential has been applied.
  • Inhalation is also understood to cover “negative” inhalation (i.e. exhalation or blowing), sucking or any other means to generate a pressure differential across the passage and/or obstruction. More generally, inhalation (and exhalation) are understood to mean applying an overpressure to an inlet and/or applying an underpressure to an outlet of the inhalation device.
  • a powder is to be understood to mean a collection of small particles or granules having, at least, a solid surface and wherein individual particles have a mean diameter preferably below one millimeter.
  • a powder may contain particles of varying size and varying size distributions. For instance, an inhalation powder may contain large particles which may tend to be more flowable as powder and small particles which may tend to be more suitable to be delivered to the deep lung.
  • inhalation powder is to be understood here broadly to cover all powders having at least a fraction of inhalation particles of appropriate size to be inhaled, sucked or blown into the mouth, throat or lung, or any other external or internal surface, passage, cavity or protuberance of an organism.
  • inhalation powders include, but are not limited to, pharmaceutical, medicinal, diagnostic, irritant, poisonous, placebo, flavoring or scent giving agent or a powder intended to have biological, chemical, medicinal or psychological effect on an organism or other powders intended to have an effect, for instance, biological, chemical, medicinal, psychological or other on an organism.
  • inhalation powders also include exhalation powders.
  • Active ingredient and Active Pharmaceutical Ingredient are here understood to mean any ingredient meant to produce an effect, positive or negative, on an organism. This may include, but are limited to, medicinal agents and drugs, diagnostic agents, irritants and poisons.
  • a passage here means a duct, passage, channel, tube or conduit and is to be understood to here broadly mean a structure having one or more inlet orifices (inlets) and one or more outlet orifices (outlets) through which a fluid (such as a liquid, gas, aquasol or aerosol) can pass.
  • a fluid such as a liquid, gas, aquasol or aerosol
  • this includes a structure which will allow a fluid to pass once an obstruction inhibiting its flow is breached.
  • a blocked passage which does not allow the flow of a fluid from an inlet to an exit, but which would allow the flow when an obstruction is breached, also constitutes a passage.
  • a passage is so defined as to include a blocked passage which may become unblocked upon activation or breaching. Examples include but are not limited to tubes, vessels with multiple orifices, straws and pipes, but more complex shapes are also possible according to the invention.
  • Breaching or activation is understood to mean dislocating, opening, rupturing or otherwise fully or partially removing or impairing or inhibiting an obstructions primary function (i.e. blocking a flow through a passage).
  • an obstructions primary function i.e. blocking a flow through a passage.
  • breach, breached, activate or activated shall be used for any of these circumstances or their functional equivalents, e.g., a passage or device is activated when an obstruction is breached.
  • the one or more inlets and outlets according to the invention can be dependent on the direction of the pressure differential under inhalation, the higher pressure orifice(s) being the inlet(s) and the lower pressure orifice(s) being the outlet(s).
  • which orifice or orifices are inlets and/or outlets can depend on over which orifices and/or in which direction the breaching pressure differential is applied.
  • An obstruction is to be understood here to mean any structure or combination of structures that block the free flow of fluid, powder and/or aerosol out of the device. These can be either upstream or downstream of the powder or both upstream and downstream of the powder.
  • an obstruction can, for instance block the airflow and aerosol powder flow (e.g. a diaphragm or membrane having low or no porousity), or can allow the airflow, but block the powder flow (e.g. a particle filter).
  • upstream and downstream refer to the conditions within the passage once an obstruction that blocks the fluid flow has been breached.
  • obstructions include but are not limited to, for instance, valves, shutters, apertures, diaphragms, meshes, fabrics, films, filters, foils, membranes, covers, hatches, caps, doors or any other such device or construction which can fully or partially open under a pressure differential.
  • the device according to the invention has at least one, but in many examples at least two obstructions which are between the inlet and the powder and between the outlet and the powder, but other configurations are possible according to the invention. It is preferable, though not necessary, that the obstruction also serves to aid in protecting the powder from external environment conditions such as moistures, oxidants, reducing agents, contaminants, electromagnetic radiation (e.g. UV light), heat, bacteria and other agents or conditions that may degrade or otherwise alter the powder before use.
  • electromagnetic radiation e.g. UV light
  • Sufficient or breaching pressure differential is here understood to mean a pressure differential between the one or more inlets and one or more outlets of the one or more passages above the normal range of pressure differentials that typically exist in the use environment of the device before activation but below the maximum pressure differential a pressure differential generating agent (such as a pump or organism) produces (e.g. with its respiratory system) before or during use.
  • a pressure differential generating agent such as a pump or organism
  • said pressure differential is termed the release, breaching or initiation pressure differential.
  • a pressure differential generating agent is here understood to mean any agent that is able to generate a breaching pressure differential across at least one of the one or more obstructions in the inhalation device.
  • An organism is here understood to mean any organism able to generate a breaching pressure differential, e.g. through inhalation. Examples include but are not limited to reptiles, birds, and mammals (including humans).
  • Figure 1 illustrates a preferred embodiment of the invention in asymmetric (a) and symmetric (b) versions before activation when the pressure differential between the inlet and outlet of the device has not yet reached the breaching pressure differential.
  • Figure 2 illustrates a preferred embodiment of the invention during use when the pressure differential between the inlet and outlet of the device has reached the breaching pressure differential and a flow has been established to aerosolize the powder and carry it from the device.
  • Figure 3 illustrates a preferred embodiment of the invention before activation having an inlet or upstream constriction.
  • Figure 4 illustrates a preferred embodiment of the invention before activation having an outlet or downstream constriction.
  • Figure 5 illustrates a preferred embodiment of the invention before activation having both an outlet and an inlet constriction. Such a configuration is useful for storing the powder and/or protecting the powder from the environment.
  • Figure 6 illustrates a preferred embodiment of the invention before activation having both an outlet and an inlet constriction with both inlet and outlet shaped for easy sealing against the users' lips.
  • Figure 7 illustrates a preferred embodiment of the invention which allows the separate production and assembly of a sealed powder capsule in conjunction with a disposable or reusable passage.
  • Figure 8 illustrates a preferred embodiment of the invention in which the entire device is stored in an individual sealed pouch for single use before disposal or refiling and in which the sealed powder capsule is stored in an individually sealed pouch before use before disposal or refiling.
  • Figure 9 illustrates a preferred use of an embodiment of the invention in which a single user inhales through the device to draw the powder into the users mouth, throat and/or lungs, a preferred use of an embodiment of the invention in which a first user exhales through the device to force the powder into a second users mouth, throat and/or lungs and a preferred use of an embodiment of the invention in a single user exhales through the device to deposit the powder onto a third users face or eyes.
  • Figure 1 shows a preferred embodiment of the invention before activation (i.e. before the breaching pressure differential is reached) where the passage is a straight tube (1 ) having an inlet (2) at pressure P in and an outlet (3) at pressure P ou t- Before use, P ou t and P, n are essentially the same.
  • the inner diameter of the tube is between 100 mm and 0.1 mm and more preferably between 10 mm and 1 mm and more preferably between 5 mm and 2 mm and most preferably, approximately 3.5 mm. More complex ducts/passages/conduits are possible according to the invention. For more complex geometries, the diameter can be translated in terms of an equivalent cross sectional area or hydraulic diameter.
  • the pressure differential (dP) is the absolute value of the difference between in inlet and outlet pressure. Before activation or in storage, the pressure differential is maintained below the breaching pressure differential (dPe).
  • the two obstructions (4) are metal foil diaphragms sealed at the inner wall of the duct.
  • Other materials and configurations are possible according to the invention such as polymers, organic membranes and papers or combinations thereof so long as they are only breached when the breaching pressure differential is reached.
  • Preferable materials for the obstruction are also barriers against, for instance, water, oxygen, UV light, viruses, bacteria or other environmental factors that can degrade or otherwise affect the inhalation powder or the efficacy of the inhalation powder.
  • One or both may also be sealed at one or both ends of the ducts, though, in the preferred embodiment, they are positioned at a sufficient distance from the end so as not to be susceptible to accidental puncture or rupture during normal handling before use.
  • the powder (5) is located in the passage between the obstructions.
  • Figure 2 shows the preferred embodiment of Figure 1 of the invention after activation (i.e. immediately after the breaching differential pressure has been reached) and wherein the duct/passage/conduit is a straight tube (1 ) having an inlet (2) at pressure P in and an outlet (3) at pressure Pout-
  • the two foil diaphragm obstructions rupture due to the pressure differential and the powder (5) is released from the volume between the obstructions (4) and flows to exit the tube through the exit orifice (3).
  • dP B is preferably between 0.01 and 100 kPa, and more preferably between 0.1 and 10 kPa and more preferably between 0.5 and 5 Pa and most preferably between 1 and 3 kPa when the obstruction is breached.
  • an inhalation device comprises at least one inhalation powder positioned in at least one passage.
  • the at least one passage has at least one exit, at least one inlet and at least one obstruction there between.
  • One or more of the obstructions is capable of blocking the movement of or containing the inhalation powder within the inhalation device before use.
  • the at least one obstruction of a passage becomes breachable upon the application of a pressure differential between the at least one exit and inlet of the passage.
  • the pressure differential required for the obstruction to become breachable must also be sufficient to at least partially aerosolize the inhalation powder.
  • the average aerosolized inhalation particle agglomerate when used for pulmonary deliver of powder, is preferably less than 1000 microns in diameter and more preferably less than 100 microns in diameter and more preferably less than 10 microns in diameter and most preferably approximately 3 microns in diameter.
  • the average aerosolized inhalation particle is preferably between 0.01 and 1000 microns in diameter and more preferably between 100 and 0.1 microns in diameter and more preferably between 10 and 1 microns in diameter and most preferably approximately 3 microns in diameter.
  • inhalation particle agglomerates contain, on average, less than 1000 inhalation particles and more preferably less than 100 inhalation particles and more preferably less than 10 inhalation particles and more preferably less than 5 inhalation particles and more preferably less than 3 inhalation particles and most preferably 2 or less inhalation particles.
  • the fine particle fraction (FPF) of aerosolized inhalation powder particles is above 10% and more preferably above 50% and more preferably above 75% and more preferably above 85% and more preferably above 90% and more preferably above 95% and more preferably above 98% and most preferably above 99%.
  • FPF is defined as fraction of particles emitted from the device that are below 5 micron in aerodynamic diameter.
  • the difference in emitted dose (ED) between a low inhalation rate and a high inhalation rate is below 80% and more preferably below 50% and more preferably below 30% and more preferably below 15% and more preferably below 10% and more preferably below 5% and more preferably below 2% and most preferably below 1 %
  • the low inhalation rate is preferably below 1 17 LPM and more preferably between 1 and 53 LPM, and more preferably between 12 and 37 LPM and more preferably between 17 and 29 LPM and more preferably between 20 and 25 LPM and more preferably between 21 and 23 LPM and most preferably approximately 22 LPM
  • the high inhalation rate is preferably above 1 LPM and more preferably between 24 and 1 17 LPM, and more preferably between 40 and 85 LPM and more preferably between 48 and 69 LPM and more preferably between 52 and 61 LPM and more preferably between 54 and 57 LPM and most preferably approximately 55 LPM.
  • the cross sectional area of the passage can vary with the range of acceptable equivalent inner or hydraulic diameters.
  • Figure 3 which also includes an upstream constriction (6), in this case in the form a step, to increase the pressure drop across the passage. It can also serve to increase the turbulence, shear force and mixing to increase the emitted dose and fine particle fraction and, in the case of pulmonary delivery of inhalation particles, further improve deep lung deposition of the inhalation particles.
  • upstream constriction, shear force or turbulence generating geometries are possible according to the invention.
  • Figure 4 Another embodiment of the present invention is shown in Figure 4 which also includes a downstream constriction (7), here in the form of a smooth converging nozzle, to control/increase the pressure drop across the passage and/or serve to increase the turbulence, shear force and mixing to increase the emitted dose and fine particle fraction and, in the case of pulmonary delivery of inhalation particles, further improve deep lung deposition of the inhalation particles.
  • a downstream constriction (7) here in the form of a smooth converging nozzle, to control/increase the pressure drop across the passage and/or serve to increase the turbulence, shear force and mixing to increase the emitted dose and fine particle fraction and, in the case of pulmonary delivery of inhalation particles, further improve deep lung deposition of the inhalation particles.
  • a downstream constriction (7) here in the form of a smooth converging nozzle
  • Figure 5 Another embodiment of the present invention is shown in Figure 5 which also includes multiple nozzle constrictions (7) to control/increase the pressure drop across passage and/or serve to increase the turbulence, shear force and mixing s as to increase the emitted dose and fine particle fraction and, in the case of pulmonary delivery of inhalation particles, further improve deep lung deposition of the inhalation particles.
  • multiple nozzle constrictions (7) to control/increase the pressure drop across passage and/or serve to increase the turbulence, shear force and mixing s as to increase the emitted dose and fine particle fraction and, in the case of pulmonary delivery of inhalation particles, further improve deep lung deposition of the inhalation particles.
  • FIG. 6 Another embodiment of the present invention is shown in Figure 6 in which the inlet (2) and outlet (3) are made to be oval in shape in order to better and more comfortably seal against the lips of the user.
  • FIG. 7a and 7b Another embodiment of the present invention is shown in Figure 7a and 7b which has a separable seam or break (8) in the passage (1 ) that allows a construction with three main elements.
  • the passage has two sections (1 a and 1 b) and the powder is contained within a sealed capsule (9) having a diaphragm or other appropriate breachable obstruction on both sides and containing one or more powders (5).
  • all or part of the entire device (10) is pre-assembled and packaged in a container for single dose use as shown in Figure 8a, for instance, in a sealed package (1 1 ) which may be unsealed immediately prior to use as shown in Figure 8b.
  • the entire device (10) can then be disposed of or returned to a manufacturer or recycler for refilling.
  • the passage can be reused and a sealed capsule (9) can be inserted before each use.
  • the sealed capsule (9) is disposed of or returned to the manufacturer or recycler for reuse.
  • the sealed capsule (9) can be individually packaged for storage before use.
  • Figure 9a shows a preferred use of an embodiment of the invention wherein a single user (12) inhales through the device through the mouth so as to draw the powder into the user's mouth, throat and/or lungs.
  • an embodiment of the device can be configured for inhalation through the nose for delivery to the nasal cavity, throat or lungs.
  • particles can be significantly smaller or larger than the optimal size for lung deliver.
  • Figure 9b shows a preferred use of the invention wherein a first user (12) exhales through the device to deposit the powder into another users (14) face or eyes. This use is appropriate for, for instance, applying an irritant an or a topical agent to a patient's or attacker eyes or skin.
  • Figure 9c shows a preferred use of the present invention, wherein the device is used by one user (12) to deliver powder to another user (13).
  • user (12) exhales (negatively inhales) or blows through the inhalation device (10) and the other user (13) either actively inhales or is passive and is exhaled into (i.e. is, at least partially, inflated).
  • This use scenario is appropriate, for instance, for treating infants or very infirm patients who are not willing or not able to inhale powder on their own.
  • a pump, bellows, vacuum, pressurized reservoir or other suitable pressure differential generating agent can be used in addition to or instead of inhalation (exhalation) by an organism.
  • the inhalation device comprises two or more separate passages and/or two or more separate powders (e.g. 5a and 5b) and/or two or more separate obstructions (4) in order to deliver one, two or more active agents and/or one, two or more doses either in parallel or in series.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé et un dispositif permettant de disperser des poudres et, en particulier, un procédé de dispersion de poudres d'inhalation selon lequel une poudre est positionnée dans un passage, le passage comportant une ou plusieurs sorties, une ou plusieurs entrées et une ou plusieurs obstructions pour bloquer le mouvement ou pour contenir la poudre dans le dispositif avant l'utilisation, après quoi un différentiel de pression de rupture entre une ou plusieurs sorties et une ou plusieurs entrées du passage est appliqué pour créer une brèche dans une ou plusieurs obstructions de sorte à générer un écoulement à travers le passage qui aérosolise entièrement ou partiellement la poudre au moyen de l'écoulement généré, ce qui permet de libérer du dispositif une poudre totalement ou partiellement aérosolisée.
PCT/US2015/016720 2014-02-21 2015-02-20 Dispositif d'inhalation et procédé permettant d'inhaler des poudres WO2015127147A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP15752858.9A EP3107606A4 (fr) 2014-02-21 2015-02-20 Dispositif d'inhalation et procédé permettant d'inhaler des poudres
CN201580006645.9A CN106255524B (zh) 2014-02-21 2015-02-20 用于吸入粉体的吸入装置
US15/119,128 US10857315B2 (en) 2014-02-21 2015-02-20 Inhalation device and method for inhaling powders
JP2016552345A JP2017506106A (ja) 2014-02-21 2015-02-20 粉末を吸入するための吸入デバイス及び方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942657P 2014-02-21 2014-02-21
US61/942,657 2014-02-21

Publications (2)

Publication Number Publication Date
WO2015127147A2 true WO2015127147A2 (fr) 2015-08-27
WO2015127147A3 WO2015127147A3 (fr) 2015-12-10

Family

ID=53879238

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/016720 WO2015127147A2 (fr) 2014-02-21 2015-02-20 Dispositif d'inhalation et procédé permettant d'inhaler des poudres

Country Status (5)

Country Link
US (1) US10857315B2 (fr)
EP (1) EP3107606A4 (fr)
JP (3) JP2017506106A (fr)
CN (1) CN106255524B (fr)
WO (1) WO2015127147A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106880894A (zh) * 2017-02-28 2017-06-23 张健 雾化器
WO2022034431A1 (fr) * 2020-08-10 2022-02-17 Giacalone Tommaso Dispositif d'administration et cartouche pour produits à inhaler

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710653D0 (en) * 2017-07-03 2017-08-16 One Hundred Flowers Ltd Inhaler

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2503732A (en) 1949-01-28 1950-04-11 Wyeth Corp Inhalator
US2642063A (en) 1948-07-31 1953-06-16 Frederick M Turnbull Inhaler
US5513630A (en) 1995-03-08 1996-05-07 Century; Theodore J. Powder dispenser
WO1999046055A1 (fr) 1998-03-10 1999-09-16 Valois S.A. Reservoir, procede de remplissage du reservoir et dispositif de distribution du produit fluide contenu dans le reservoir
WO2003095011A1 (fr) 2002-05-10 2003-11-20 Becton, Dickinson And Company Cartouche et dispositif pour l'administration de medicament au niveau respiratoire
GB2405350A (en) 2003-08-28 2005-03-02 Optinose As A nasal delivery device operated by exhalation into a mouthpiece
US20070175476A1 (en) 2005-12-28 2007-08-02 Philip Morris Usa Inc. Aerosol powder delivery device
US20100309020A1 (en) 2007-11-22 2010-12-09 Siegfried Generics International Ag Metering Device for the Inhalation of a Pulverulent Substance
US20110126830A1 (en) 2006-11-28 2011-06-02 Optinose As Delivery devices
US20130092161A1 (en) 2004-08-27 2013-04-18 Alfred Von Schuckmann Inhaler For Powdered, Particularly Medical Substances
WO2013087788A1 (fr) 2011-12-16 2013-06-20 Sanofi Sa Dispositif d'administration d'un médicament en poudre à un patient par inhalation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39678A (en) * 1863-08-25 Improvement in powder-injectors
US32789A (en) * 1861-07-09 seguitz
US2672144A (en) * 1951-11-19 1954-03-16 Milton J Cohen Powder dispenser
US3831606A (en) 1971-02-19 1974-08-27 Alza Corp Auto inhaler
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
US3948264A (en) 1975-05-21 1976-04-06 Mead Johnson & Company Inhalation device
DE2716323C2 (de) 1977-04-07 1986-03-13 Schering AG, 1000 Berlin und 4709 Bergkamen Vorrichtung zur Inhalation von Arzneimitteln
US4265236A (en) * 1980-03-31 1981-05-05 Pacella Angelo M Portable inhalator device
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
US4387474A (en) * 1981-09-23 1983-06-14 Schierloh J Calvin Beehive medicator
US5113855A (en) 1990-02-14 1992-05-19 Newhouse Michael T Powder inhaler
GB9021433D0 (en) 1990-10-02 1990-11-14 Atomic Energy Authority Uk Power inhaler
US5327883A (en) 1991-05-20 1994-07-12 Dura Pharmaceuticals, Inc. Apparatus for aerosolizing powdered medicine and process and using
US5161524A (en) 1991-08-02 1992-11-10 Glaxo Inc. Dosage inhalator with air flow velocity regulating means
DE4211475A1 (de) 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
DE69413989T2 (de) 1993-08-18 1999-04-08 Fisons Plc Inhalator mit atemstromregelung
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5483954A (en) * 1994-06-10 1996-01-16 Mecikalski; Mark B. Inhaler and medicated package
US5797392C1 (en) * 1996-01-22 2001-01-09 Direct Haler As Inhaler
US5699789A (en) * 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
GB9810126D0 (fr) * 1998-05-13 1998-07-08 Glaxo Group Ltd
US20050196345A1 (en) 1999-02-03 2005-09-08 Max-Delbruck-Centrum Fur Molekulare Medizin Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols
JP2004515467A (ja) * 2000-08-07 2004-05-27 ネクター セラピューティックス 吸入可能な、噴霧乾燥した、最少の凝集物を有する４−ヘリックスバンドルタンパク質粉末
GB0024793D0 (en) * 2000-10-10 2000-11-22 Innovata Biomed Ltd Diaphragm
US6644309B2 (en) 2001-01-12 2003-11-11 Becton, Dickinson And Company Medicament respiratory delivery device and method
US6722364B2 (en) * 2001-01-12 2004-04-20 Becton, Dickinson And Company Medicament inhalation delivery devices and methods for using the same
GB0130284D0 (en) * 2001-12-19 2002-02-06 Glaxo Group Ltd Medicament dispenser
WO2008048234A2 (fr) * 2005-08-26 2008-04-24 North Carolina State University Système inhalateur destiné à une administration ciblée maximale de médicaments en aérosol
US9381410B2 (en) 2014-05-07 2016-07-05 Acushnet Company Metal wood club

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642063A (en) 1948-07-31 1953-06-16 Frederick M Turnbull Inhaler
US2503732A (en) 1949-01-28 1950-04-11 Wyeth Corp Inhalator
US5513630A (en) 1995-03-08 1996-05-07 Century; Theodore J. Powder dispenser
WO1999046055A1 (fr) 1998-03-10 1999-09-16 Valois S.A. Reservoir, procede de remplissage du reservoir et dispositif de distribution du produit fluide contenu dans le reservoir
WO2003095011A1 (fr) 2002-05-10 2003-11-20 Becton, Dickinson And Company Cartouche et dispositif pour l'administration de medicament au niveau respiratoire
GB2405350A (en) 2003-08-28 2005-03-02 Optinose As A nasal delivery device operated by exhalation into a mouthpiece
US20130092161A1 (en) 2004-08-27 2013-04-18 Alfred Von Schuckmann Inhaler For Powdered, Particularly Medical Substances
US20070175476A1 (en) 2005-12-28 2007-08-02 Philip Morris Usa Inc. Aerosol powder delivery device
US20110126830A1 (en) 2006-11-28 2011-06-02 Optinose As Delivery devices
US20100309020A1 (en) 2007-11-22 2010-12-09 Siegfried Generics International Ag Metering Device for the Inhalation of a Pulverulent Substance
WO2013087788A1 (fr) 2011-12-16 2013-06-20 Sanofi Sa Dispositif d'administration d'un médicament en poudre à un patient par inhalation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106880894A (zh) * 2017-02-28 2017-06-23 张健 雾化器
WO2022034431A1 (fr) * 2020-08-10 2022-02-17 Giacalone Tommaso Dispositif d'administration et cartouche pour produits à inhaler

Also Published As

Publication number Publication date
US10857315B2 (en) 2020-12-08
EP3107606A2 (fr) 2016-12-28
JP2017506106A (ja) 2017-03-02
CN106255524B (zh) 2020-03-24
JP2021007815A (ja) 2021-01-28
JP7477246B2 (ja) 2024-05-01
EP3107606A4 (fr) 2017-11-01
US20170065779A1 (en) 2017-03-09
WO2015127147A3 (fr) 2015-12-10
CN106255524A (zh) 2016-12-21
JP2022140723A (ja) 2022-09-27

Similar Documents

Publication Publication Date Title
US11752282B2 (en) Dry powder inhalation device
US11471623B2 (en) Powder dispersion methods and devices
JP7477246B2 (ja) 粉末を吸入するための吸入デバイス及び方法
JP7189149B2 (ja) 乾燥粉末吸入器および乾燥粉末吸入器用スペーサ装置
US10682476B2 (en) Powder inhaler, system and methods
EP3099364B1 (fr) Compartiment à poudre pour l'administration de médicament en dose élevée
US20230302236A1 (en) Devices, systems, and methods for dry powder therapies
EP3302661B1 (fr) Inhalateur de poudre sèche à dose unique
US20230001114A1 (en) Powder dispersion methods and devices

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2016552345

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15119128

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015752858

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015752858

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15752858

Country of ref document: EP

Kind code of ref document: A2